多西他赛联合顺铂治疗蒽环类耐药晚期乳腺癌疗效分析

Docetaxel combined with cisplatin in treatment of anthracycline-resistant advanced breast cancer

目的:观察多西他赛联合顺铂治疗蒽环类耐药晚期乳腺癌疗效及安全性。方法:多西他赛75mg/m2,静脉滴注,第1天;顺铂25mg/m2,静脉滴注,第1～3天,21天为1周期,2周期后评价疗效。结果:35例均可评价疗效,完全缓解(CR)5例,部分缓解(PR)19例,稳定(SD)6例,进展(PD)5例,总有效率(CR+PR)68.6%。毒副反应为恶心、呕吐、脱发和骨髓抑制。结论:多西他赛联合顺铂治疗蒽环类耐药晚期乳腺癌疗效较好,毒副反应可耐受,可作为该类患者的治疗选择。

Objective：To evaluate the efficacy and safety of Docetaxel combined with cisplatin in treatment of anthracycline-resistant advanced breast cancer. Methods：Docetaxel 75 mg/m^2 intravenous drip was given at dl and cisplatin 25 mg/m^2 was given intravenous drip at d1 - 3. One cycle consisted of 3 weeks. The clinical response was assessed after two cycles. Results： Of the 35 patients, 5 achieved complete remission, 19 partial remission,6 SD and 5 PD, with a response rate of 68.6%. The main side effects were vomiting, alopecia and neutropenia. Conclusions： Docetaxe and displatin combination is effective on anthracycine-resistant advanced breast cancer with acceptable toxicity. It provides an alternative for patients with advanced breast cancer.